Related Experiment Video

Updated: May 15, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Association between the G252A Tumor Necrosis Factor-β Gene Polymorphism and Medication-Overuse Headache

Masakazu Ishii1, Tomomi Onaya, Hirotaka Katoh

  • 1Department of Pathophysiology, Showa University School of Pharmacy, Tokyo, Japan.

Journal of Clinical Neurology (Seoul, Korea)
|January 17, 2013
PubMed
Abstract

Insights

Tumor necrosis factor-beta (TNF-β) gene G252A polymorphism may influence medication-overuse headache (MOH) risk. G/G genotype carriers show reduced susceptibility to MOH, suggesting a protective role.

Area of Science:

  • Genetics
  • Neurology
  • Pharmacology

Background:

  • Migraine patients frequently develop medication-overuse headache (MOH).
  • The tumor necrosis factor-beta (TNF)-β gene G252A polymorphism is linked to migraine without aura.
  • The association between TNF-β G252A polymorphism and MOH is currently unknown.

Purpose of the Study:

  • To investigate the role of the TNF-β gene G252A polymorphism in the development of MOH.
  • To determine if TNF-β G252A polymorphism influences migraine aggravation due to medication overuse.

Main Methods:

  • Genotyping of the TNF-β gene G252A polymorphism using polymerase-chain-reaction restriction-fragment-length polymorphism analysis.
  • Comparison of genotype frequencies between 47 migraine patients and 22 MOH patients.

Main Results:

  • Significant differences in TNF-β gene G252A genotype distribution were observed between migraine and MOH patient groups (p=0.013).
  • The G/G genotype was present in 23% of migraine patients but was entirely absent in MOH patients.

Conclusions:

  • Individuals with the G/G genotype appear less prone to developing MOH from medication overuse.
  • The G252A TNF-β gene polymorphism may be a contributing factor in MOH development among migraine sufferers.
Keywords:
medication overuse headachemigrainetumor necrosis factor gene

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...